Drug
Eteplirsen clinical trials
Also written AVI-4658.
- studies test it
- 11
- open now
- 0
- in phase 3
- 2
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
11 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 9
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 2
Sarepta Therapeutics, Inc. (9) · Kevin Flanigan (1) · Imperial College London (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses eteplirsen is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)Active, not recruitingPhase 3Sarepta Therapeutics, Inc.NCT03992430Written as Eteplirsen
- A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.CompletedPhase 2Kevin FlaniganNCT04179409Written as Exondys 51
- A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)TerminatedPhase 2Sarepta Therapeutics, Inc.NCT03985878Written as Eteplirsen
- Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 SkippingCompletedPhase 2Sarepta Therapeutics, Inc.NCT03218995Written as Eteplirsen
- Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular DystrophyCompletedPhase 2Sarepta Therapeutics, Inc.NCT02420379Written as eteplirsen
- Study of Eteplirsen in DMD PatientsCompletedPhase 3Sarepta Therapeutics, Inc.NCT02255552Written as eteplirsen
- Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy PatientsCompletedPhase 2Sarepta Therapeutics, Inc.NCT01396239Written as AVI-4658 (Eteplirsen)
- Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular DystrophyCompletedPhase 2Sarepta Therapeutics, Inc.NCT01540409Written as AVI-4658 (Eteplirsen)
- Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular DystrophyCompletedPhase 2Sarepta Therapeutics, Inc.NCT02286947Written as Eteplirsen
- Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular DystrophyCompletedPhase 1/2Imperial College LondonNCT00159250Written as AVI-4658 (PMO)
- Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) PatientsCompletedPhase 1/2Sarepta Therapeutics, Inc.NCT00844597Written as AVI-4658 for Injection
Codes
What other systems call eteplirsen · ClinicalTrials.gg INT000538
- MeSH (NLM) C000611335eteplirsenConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) AIW6036FASETEPLIRSENConfirmed FDA, NLM, Wikidata
- RxNorm 1810569Confirmed FDA, Wikidata
- Wikidata Q5402585eteplirsenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171739EteplirsenOne source FDA
- DrugBank DB06014One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000611335 | eteplirsen | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | AIW6036FAS | ETEPLIRSEN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1810569 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5402585 | eteplirsen | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171739 | Eteplirsen | One source FDA |
| DrugBank | DB06014 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.